These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12041766)

  • 1. Imipenem-cilastatin in the treatment of hospital infections.
    Mao P; Enrichens F; Olivero G; Sciascia C; Benedetto G; Franchello A; Olivero S
    J Chemother; 1991 Jan; 3 Suppl 1():205-7. PubMed ID: 12041766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imipenem/cilastatin as empirical treatment of severe infections in compromised patients.
    Biglino A; Bonasso M; Gioannini P
    J Chemother; 1991 Jan; 3 Suppl 1():208-12. PubMed ID: 12041767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem.
    Richerson MA; Ambrose PG; Quintiliani R; Nightingale CH
    Conn Med; 1998 Mar; 62(3):165-9. PubMed ID: 9573653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalized patients with severe pneumonia.
    Caldwell JW; Singh S; Johnson RH
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():129-34. PubMed ID: 10225583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imipenem in acute lung infections and bacterial re-exacerbations of chronic obstructive lung disease.
    Pozzi E; De Rose V
    J Chemother; 1991 Jan; 3 Suppl 1():213-7. PubMed ID: 12041768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative study of the cost-/effectiveness relationship of initial therapy with imipenem/cilastatin in nosocomial pneumonia. Group study].
    Rodloff AC; Laubenthal HJ; Bastian A; Bestehorn K; Büchele G; Gaus W
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1996 Apr; 31(3):172-80. PubMed ID: 8672620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and clinical evaluation of serious infections in premature and newborn infants under therapy with imipenem/cilastatin.
    Böswald M; Döbig C; Kändler C; Krüger C; Scharf J; Soergel F; Zink S; Guggenbichler JP
    Infection; 1999; 27(4-5):299-304. PubMed ID: 10885853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Imipenem in the treatment of patients with severe surgical infection].
    Szczygieł B; Pertkiewicz M; Meszaros J; Otto M; Grochowiecki T; Rudnicka J; Hacel I; Solecka-Lasak M
    Pol Tyg Lek; 1992 Jul 20-27; 47(29-30):638-41. PubMed ID: 1488347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imipenem use in serious childhood infections.
    Pavesio D; Pecco P; Giacchino M; Dotti M
    J Chemother; 1991 Jan; 3 Suppl 1():218-21. PubMed ID: 12041769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in clinically separated strains of glucose non-fermented gram-negative bacilli following the induction of imipenem/cilastatin.
    Fujita J; Negayama K; Higuchi K; Nakano M; Yamaji Y; Irino S
    J Intern Med; 1991 Jun; 229(6):558-9. PubMed ID: 2045767
    [No Abstract]   [Full Text] [Related]  

  • 11. How should imipenem-cilastatin be used in the treatment of fever and infection in neutropenic cancer patients?
    Raad II; Abi-Said D; Rolston KV; Karl CL; Bodey GP
    Cancer; 1998 Jun; 82(12):2449-58. PubMed ID: 9635539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia.
    Joshi M; Metzler M; McCarthy M; Olvey S; Kassira W; Cooper A
    Respir Med; 2006 Sep; 100(9):1554-65. PubMed ID: 16487695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for ICU-acquired imipenem-resistant Gram-negative bacterial infections.
    Akinci E; Colpan A; Bodur H; Balaban N; Erbay A
    J Hosp Infect; 2005 Apr; 59(4):317-23. PubMed ID: 15749320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of teicoplanin and imipenem on respiratory infections in high risk patients.
    Piu G; Aresu G; Pautasso M; Garau G; Melis S; Ceccio S; Morini M; Palomba A
    J Chemother; 1991 Jan; 3 Suppl 1():222-3. PubMed ID: 12041770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness of imipenem/cilastatin (Tienam, MSD) in treating complicated infections in urology].
    Derevianko II; Nefedova LA; Lavrinova LN
    Urologiia; 2002; (3):21-5. PubMed ID: 12180053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Imipenem resistance in Gram-negative rods and its consumption between 1999 and 2005].
    Gospodarek E; Gierlotka K; Deptuła A; Michalska A
    Med Dosw Mikrobiol; 2007; 59(3):231-40. PubMed ID: 18078118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imipenem/cilastatin: monotherapy of hospital infections.
    Scand J Infect Dis Suppl; 1987; 52():1-78. PubMed ID: 3483285
    [No Abstract]   [Full Text] [Related]  

  • 18. Hospital acquired native valve endocarditis caused by Acinetobacter calcoaceticus and treated with imipenem/cilastin.
    Cumberland NS; Jones KP
    J R Army Med Corps; 1987 Oct; 133(3):156-8. PubMed ID: 3479562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance patterns among selective Gram-negative bacilli from an intensive care unit in Trinidad, West Indies.
    Orrett FA
    Saudi Med J; 2004 Apr; 25(4):478-83. PubMed ID: 15083220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial.
    Geddes A; Thaler M; Schonwald S; Härkönen M; Jacobs F; Nowotny I
    J Antimicrob Chemother; 1999 Dec; 44(6):799-810. PubMed ID: 10590282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.